Bevacizumab
info General information
Name Bevacizumab, 25 mg/mL, concentrate for solution for infusion
INN Bevacizumab
Active substance Bevacizumab
Pharmacotherapeutic group Antineoplastic agents. Monoclonal antibodies and antibody conjugates. VEGF/VEGFR (vascular endothelial growth factor) inhibitors. Bevacizumab
Dosage form Concentrate for solution for infusion
Packaging
4 mL or 16 mL of the product in a vial. 1 vial (4 mL or 16 mL) is placed in a cardboard box.
Manufacturer Karaganda Pharmaceutical Complex LLP
EU GMP
assignment_turned_in Indications
Bevacizumab is used to treat adult patients with:
- advanced colorectal cancer, in combination with fluoropyrimidine-based chemotherapy.
- metastatic breast cancer, in combination with capecitabine or paclitaxel.
- non-small cell lung cancer, in combination with platinum-based chemotherapy.
- advanced non-small cell lung cancer in which the cancer cells have specific mutations of a protein called epidermal growth factor receptor (EGFR). Bevacizumab will be given in combination with erlotinib.
- kidney cancer, in combination with medicines called interferons.
- advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, in combination with carboplatin and paclitaxel.
- advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in which symptoms have returned at least 6 months after the last platinum-based chemotherapy. These patients will receive Bevacizumab in combination with carboplatin and gemcitabine.
- advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in which symptoms have returned less than 6 months after the last platinum-based chemotherapy. These patients will receive Bevacizumab in combination with paclitaxel, or topotecan, or pegylated liposomal doxorubicin.
- persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan if the patient cannot receive platinum therapy.
